# CareDx, Inc.: Form 10-Q for the period ended Sep 30, 2019

- Company: [CareDx, Inc.](/companies/cdna.md) (CIK 1217234)
- Form: 10-Q
- Filed: 2019-10-31
- Accepted by EDGAR: Oct 31, 2019, 17:28 ET
- Period: 2019-09-30
- Accession: 0001628280-19-012991
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1217234/000162828019012991/cdna-20190930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1217234/000162828019012991/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $33.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $91.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $11.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $32.7m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $22.3m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $58.5m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-07-01 to 2019-09-30 | $8.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-01-01 to 2019-09-30 | $21.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | −$6.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | −$19.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | −$949.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | −$1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | −$1.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | −$17.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | −$0.41 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-01-01 to 2019-09-30 | −$0.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-30 | 42,393,550 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-01-01 to 2019-09-30 | 42,048,647 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | −$1.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $970.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-09-30 | $40.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $68.1m | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $144.8m | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $31.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $47.3m | us-gaap:Liabilities |
| Long-term debt | at 2019-09-30 | $0 | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2019-09-30 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2019-09-30 | $97.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 52,454 characters.

*The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included elsewhere in Item 1 of Part I of this Quarterly Report on Form 10-Q and with the audited consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities and Exchange Commission, or the SEC, on March 6, 2019.*

### SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and the negative and plural forms of these words and similar expressions are intended to identify forward-looking statements.

These forward-looking statements may include, but are not limited to, statements concerning the following:

- our ability to generate revenue from sales of AlloMap Heart, AlloSure Kidney and future testing services, if any, and our ability to increase the commercial success of these testing services;
- our ability to obtain, maintain and expand reimbursement coverage from payers for AlloMap Heart, AlloSure Kidney and other future testing services, including AlloMap Kidney, AlloSure Heart, AlloSure Lung and KidneyCare iBox, if any;
- our ability to generate revenue from sales of Olerup SSP, Olerup SBT, QTYPE, TruSight HLA and future products, if any, and our ability to increase the commercial success of these products;
- our ability to generate revenue from the license and commercialization agreement, or the License Agreement with Illumina, Inc., or Illumina;
- our ability to generate revenue from the license and commercialization agreement, or the Cibiltech Agreement, with Cibiltech SAS, or Cibiltech;
- our plans and ability to develop and commercialize new solutions for the surveillance of heart, kidney and other solid organ transplant recipients;
- our plans and ability to continue updating our products, services and technology to maintain our leading position in transplantations;
- the outcome or success of our clinical trial collaborations and registry studies; including Kidney Allograft Outcomes AlloSure Registry, or K-OAR, the Surveillance HeartCare Outcomes Registry, or SHORE, and the Outcomes of KidneyCare on Renal Allografts registry study, or OKRA;
- the favorable review of our testing services and product offerings, and our future solutions, if any, in peer-reviewed publications;
- our ability to obtain additional financing on terms favorable to us, or at all;
- our anticipated cash needs and our anticipated uses of our funds, including our estimates regarding operating expenses and capital requirements;
- our ability to integrate our business with the business of Ottr Complete Transplant Management, or Ottr, and to realize the anticipated benefits of the acquisition;
- our ability to integrate our business with the business of XynManagement, Inc., or XynManagement, and to realize the anticipated benefits of the acquisition;
- anticipated trends and challenges in our business and the markets in which we operate;
- our dependence on certain of our suppliers, service providers and other distribution partners;
- disruptions to our business, including disruptions at our laboratories and manufacturing facilities;
- our ability to retain key members of our management team;
- our ability to make successful acquisitions or investments and to manage the integration of such acquisitions or investments;
- our ability to expand internationally;
- our compliance with federal, state and foreign regulatory requirements;
- our ability to protect and enforce our intellectual property rights, our strategies regarding filing additional patent applications to strengthen our intellectual property rights and our ability to defend against intellectual property claims that may be brought against us;
- our ability to successfully assert or defend against, or settle, any litigation brought by or against us or other legal matters or disputes; and
- our ability to comply with the requirements of being a public company.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section entitled “Risk Factors” in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 6, 2019. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially and adversely from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.

You should read this report and the documents that we reference in this report and have filed with the SEC as exhibits with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. We qualify all forward-looking statements by these cautionary statements.

### Overview and Recent Highlights

We are a global transplant diagnostics company with product and service offerings along the pre- and post-transplant continuum. We focus on discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. We also offer high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs.

### Testing Services

### AlloMap Heart

Our first commercialized testing solution, the AlloMap Heart transplant molecular test, or AlloMap Heart, is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate-to-severe acute cellular rejection. Since 2008, we have sought to expand the adoption and utilization of our AlloMap Heart solution through ongoing studies to substantiate the clinical utility and actionability of AlloMap Heart, secure positive reimbursement decisions for AlloMap Heart from large private and public payers, develop and enhance our relationships with key members of the transplant community, including opinion leaders at major transplant centers, and explore opportunities and technologies for the development of additional solutions for post-transplant surveillance. We believe the use of AlloMap Heart, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant. In particular, we believe AlloMap Heart can improve patient care by helping healthcare providers avoid the use of unnecessary, invasive surveillance biopsies and determine the appropriate dosage levels of immunosuppressants. In 2008, AlloMap Heart received 510(k) clearance from the U.S. Food and Drug Administration for marketing and sale as a test to aid in the identification of recipients with a low probability of moderate or severe acute cellular rejection.

AlloMap Heart received a positive coverage decision for reimbursement from Medicare effective January 1, 2006. The Medicare reimbursement rate for AlloMap Heart was set as $3,240 on January 1, 2018, which remains applicable for 2019. AlloMap Heart has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers, including Aetna, Anthem, Cigna, Health Care Services Corporation (HCSC), Humana, Kaiser Foundation Health Plan, Inc., TRICARE and UnitedHealthcare.

We have also successfully completed a number of landmark clinical trials in the transplant field demonstrating the clinical utility of AlloMap Heart for surveillance of heart transplant recipients. We initially established the analytical and clinical validity of AlloMap Heart on the basis of our Cardiac Allograft Rejection Gene Expression Observational (Deng, M. et al., Am J Transplantation 2006), or CARGO, study, which was published in the American Journal of Transplantation. A subsequent clinical utility trial, Invasive Monitoring Attenuation through Gene Expression (Pham MX et al., N. Eng. J. Med., 2010), or IMAGE, published in The New England Journal of Medicine, demonstrated that clinical outcomes in recipients managed with AlloMap Heart surveillance were equivalent (non-inferior) to outcomes in recipients managed with biopsies. The results of our clinical trials have also been presented at major medical society congresses. AlloMap Heart is now recommended as part of the International Society for Heart and Lung Transplantation, or ISHLT, guidelines.

During the first nine months of 2019, there were 13,578 AlloMap Heart patient test results provided to 121 of the approximately 136 heart transplant management centers in the United States.

### AlloSure Kidney

AlloSure Kidney, our transplant surveillance solution which was commercially launched in October 2017, applies proprietary next generation sequencing technology to measure donor-derived cell-free DNA, or dd-cfDNA, in the blood stream emanating from the donor kidney. We believe AlloSure Kidney may help clinicians determine rejection-specific activity manifested as cell damage in the transplanted heart, kidney, or other solid organ, irrespective of the type of organ transplanted. We also believe the use of AlloSure Kidney, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a kidney transplant. In particular, we believe AlloSure Kidney can improve patient care by helping healthcare providers to reduce the use of invasive biopsies and determine the appropriate dosage levels of immunosuppressants. Effective October 9, 2017, AlloSure Kidney became available for commercial testing with Medicare coverage and reimbursement. The Medicare reimbursement rate for AlloSure Kidney is $2,841. AlloSure Kidney has also received payment from private payers on a case-by-case basis, but no positive coverage decisions have been made to the date of this filing.

Prior to the commercialization of AlloSure Kidney, we generated a strong body of clinical evidence. In late 2015, we announced the completion of analytical validation of AlloSure Kidney. A report describing the analytical validation of AlloSure Kidney including clinical validation detailing the quality, reality and consistency of analytical results information for heart transplant, appeared in the November 2016 issue of The Journal of Molecular Diagnostics. The Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients, or DART, trial, sponsored by us, was conducted between April 2015 and January 2018. DART is a 14 center observational study of kidney transplant recipients where blood specimens are drawn periodically after transplant during follow up visits and also after treatment for acute rejection. By the time of completion of the first analysis, 384 patients were followed in DART for up to 24 months. The results demonstrated that increased levels of dd-cfDNA, determined by the AlloSure Kidney assay, discriminated active rejection of a kidney transplant more effectively than serum creatinine values. In collaboration with clinical investigators, we published these findings in the scientific peer-reviewed Journal of the American Society of Nephrology and the Journal Applied Laboratory Medicine in March 2017. A total of 2,109 patient visits had been accrued in DART by January 2019. We analyzed this data to report on additional findings from this dataset at the American Transplant Congress ("ATC") 2019 and intend to continue to report into the future.

In 2018, we initiated the Kidney Allograft Outcomes AlloSure Registry, or K-OAR study, to develop further data on the clinical utility of AlloSure Kidney for surveillance of kidney transplant recipients. As of September 30, 2019, 55 centers have been initiated as K-OAR study sites.

During the first nine months of 2019, there were 21,589 AlloSure Kidney patient test results provided. In the third quarter of 2019, AlloSure Kidney was ordered by 124 kidney transplant centers in the United States.

### HeartCare

In September 2018, we initiated the SHORE study. SHORE is a prospective, multi-center, observational, registry of patients receiving HeartCare for surveillance.

HeartCare combines the gene expression profiling technology of AlloMap Heart with the dd-cfDNA analysis of AlloSure Heart in one surveillance solution. An approach to surveillance using HeartCare provides information from two complementary measures: (i) AlloMap Heart – a measure of immune activity, and (ii) AlloSure Heart – monitors graft injury. HeartCare provides robust information about distinct biological processes, such as immune quiescence, active injury, Acute Cellular Rejection, or ACR, and Antibody Mediated Rejection, or AMR. We have not yet made any applications to private payers for reimbursement coverage of AlloSure Heart except for Medicare.

### KidneyCare

In September 2019, we announced the enrollment of the first patient in the OKRA study, which is an extension of the K-OAR study. OKRA is a prospective, multi-center, observational registry of patients receiving KidneyCare for surveillance. KidneyCare combines the dd-cfDNA analysis of AlloSure Kidney with the gene expression profiling technology of AlloMap Kidney and the predictive artificial intelligence technology of KidneyCare iBox in one surveillance solution. We have not yet made any applications to payers for reimbursement coverage of AlloMap Kidney or KidneyCare iBox.

### AlloSure Lung

In February 2019, AlloSure Lung became available for lung transplant patients through a compassionate use program while the test is undergoing further studies. AlloSure Lung applies proprietary next generation sequencing, or NGS, technology to measure dd-cfDNA in the blood stream emanating from the donor lung to monitor graft injury. We have not yet made any applications to payers for reimbursement coverage of AlloSure Lung.

### Products

We develop, manufacture, market and sell products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs.

QTYPE enables speed and precision in Human Leukocyte Antigen, or HLA typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time polymerase chain reaction, or PCR, methodology. QTYPE received CE mark certification on April 10, 2018. Olerup SSP is used to type HLA alleles based on the sequence specific primer, or SSP technology. Olerup SBT is a complete product range for sequence-based typing of HLA alleles.

On May 4, 2018, we entered into the License Agreement with Illumina, which provides us with worldwide distribution, development and commercialization rights to Illumina’s NGS product line for use in transplantation diagnostic testing.

As a result, on June 1, 2018, we became the exclusive worldwide distributor of Illumina’s TruSight HLA product line. TruSight HLA is a high resolution solution that uses NGS methodology. In addition, we were granted the exclusive right to develop and commercialize other NGS product lines. These products include: AlloSeq Tx, a high-resolution HLA typing solution, AlloSeq cfDNA, our surveillance solution designed to measure dd-cfDNA in blood to detect active rejection in transplant recipients, and AlloSeq HCT, a NGS solution for chimerism testing for stem cell transplant recipients.

### Digital

On May 7, 2019, we acquired 100% of the outstanding common stock of Ottr for total consideration of $16.1 million. Ottr was formed in 1993 and is a leading provider of transplant patient tracking software, or the Ottr software.

The Ottr software provides comprehensive solutions for transplant patient management, and is currently used in over 60 leading transplant centers in the U.S. Ottr software enable integration with electronic medical records, or EMR systems, including Cerner and Epic, providing patient surveillance management tools and outcomes data to transplant centers.

On August 26, 2019, we acquired 100% of the outstanding common stock of XynManagement with a combination of cash consideration of $2.0 million paid upfront and contingent consideration with a fair value of $1.4 million. XynManagement provides two unique solutions, XynQAPI software, or XynQAPI, and Waitlist Management. XynQAPI simplifies transplant quality tracking and Scientific Registry of Transplant Recipients, or SRTR, reporting. Waitlist Management includes a team of transplant assistants who maintain regular contact with patients on the waitlist to help prepare for their transplant and maintain eligibility. XynManagement products will be added to the CareDx Digital Solutions portfolio and be integrated with current offerings, including Ottr software and patient care managers.

For additional information regarding the XynManagement acquisition, refer to Note 5, Business Combinations, of the notes to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

### Recent Highlights

- Achieved total revenue of $33.8 million for the three months ended September 30, 2019, increasing 60% year-over-year
- Provided 8,524 AlloSure Kidney patient results for 6,597 kidney transplant patients
- Provided 4,726 AlloMap Heart patient results, increasing 16% year-over-year
- Enrolled the first patient in OKRA, a new landmark registry study
- Launched AlloSeq Tx 17 and AlloSeq cfDNA globally
- Generated GAAP net loss of $1.8 million, non-GAAP net income of $0.9 million, and positive adjusted EBITDA of $0.8 million

### Financial Operations Overview

#### Revenue

We derive our revenue from testing services, products sales and digital and other revenues. Revenue is recorded considering a five-step revenue recognition model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when, or as, an entity satisfies a performance obligation.

#### Testing Services Revenue

Our testing services revenue is derived from AlloMap Heart and AlloSure Kidney, which represented 83% of our total revenues for each of the three and nine months ended September 30, 2019, and 80% and 78% of our total revenues for the three and nine months ended September 30, 2018, respectively. Our testing services revenue depends on a number of factors, including (i) the number of tests performed; (ii) establishment of coverage policies by third-party insurers and government payers; (iii) our ability to collect from payers with whom we do not have positive coverage determination, which often requires that we pursue a case-by-case appeals process; (iv) our ability to recognize revenues on tests billed prior to the establishment of reimbursement policies, contracts or payment histories; (v) our ability to expand into markets outside of the United States; and (vi) how quickly we can successfully commercialize new product offerings.

We currently market testing services to healthcare providers through our direct sales force that targets transplant centers and their physicians, coordinators and nurse practitioners. The healthcare providers that order the tests and on whose behalf we provide our testing services are generally not responsible for the payment of these services. Amounts received by us vary from payer to payer based on each payer’s internal coverage practices and policies. We generally bill third-party payers upon delivery of a test result report to the ordering physician. As such, we take the assignment of benefits and the risk of collection from the third-party payer and individual patients.

During the nine months ended September 30, 2019, we performed 13,578 commercial AlloMap Heart tests and 21,589 AlloSure Kidney tests that are included in our estimated testing services revenue. All tests for both AlloMap Heart and AlloSure Kidney were performed from our Brisbane, California laboratory.

#### Product Revenue

Our product revenue is derived primarily from sales of Olerup SSP, QTYPE, Olerup SBT and TruSight products. Product revenue represented 12% and 14% of total revenue for the three and nine months ended September 30, 2019, respectively, and 20% and 21% of our total revenues for the three and nine months ended September 30, 2018, respectively. We recognize product revenue from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied, which is generally upon either shipping or delivery, as per the terms of the agreement.

#### Digital and Other Revenue

Our digital and other revenue is mainly derived from sales of our Ottr software and XynQAPI licenses and services and other licensing agreements. Digital and other revenue represented 4% and 3% of total revenue for the three and nine months ended

September 30, 2019, respectively, and 1% of our total revenues for each of the three and nine months ended September 30, 2018.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the following critical accounting policies reflect the more significant estimates and assumptions used in the preparation of our financial statements. We believe the following critical accounting policies are affected by significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements:

- Revenue recognition;
- Business combination;
- Acquired intangible assets;
- Impairment of goodwill, intangible assets and other long-lived assets;
- Common stock warrant liability; and
- Derivative liability.

There were no material changes in the matters for which we make critical accounting estimates in the preparation of our unaudited condensed consolidated financial statements during the three and nine months ended September 30, 2019 as compared to those disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our annual report on Form 10-K for the year ended December 31, 2018, except that there is no derivative liability outstanding as of December 31, 2018 and September 30, 2019 and the determination of the leases incremental borrowing rate estimate as discussed in Note 2, Summary of Significant Accounting Policies, in the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

### Recently Issued Accounting Standards

Refer to Note 2, Summary of Significant Accounting Policies - Recent Accounting Pronouncements, of the Notes to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial position and cash flows.

### Results of Operations

### Comparison of the Three Months Ended September 30, 2019 and 2018

### (In thousands)

| Revenue: | Three Months Ended September 30, 2019 | 2018 | Change |
| --- | ---: | ---: | ---: |
| Testing services revenue | $28,226 | $16,847 | $11,379 |
| Product revenue | 4,200 | 4,223 | (23) |
| Digital and other revenue | 1,385 | 114 | 1,271 |
| Total revenue | 33,811 | 21,184 | 12,627 |
| Cost of revenue | 11,494 | 8,887 | 2,607 |
| Gross profit | 22,317 | 12,297 | 10,020 |
| Operating expenses: |  |  |  |
| Research and development | 8,521 | 3,868 | 4,653 |
| Sales and marketing | 11,058 | 5,971 | 5,087 |
| General and administrative | 9,485 | 5,177 | 4,308 |
| Total operating expenses | 29,064 | 15,016 | 14,048 |
| Loss from operations | (6,747) | (2,719) | (4,028) |
| Other income (expense): |  |  |  |
| Interest income (expense), net | 37 | (408) | 445 |
| Change in estimated fair value of common stock warrant liability and derivative liability | 4,346 | (17,093) | 21,439 |
| Other expense, net | (398) | (40) | (358) |
| Total other income (expense) | 3,985 | (17,541) | 21,526 |
| Loss before income taxes | (2,762) | (20,260) | 17,498 |
| Income tax benefit | 949 | 290 | 659 |
| Net loss | (1,813) | (19,970) | 18,157 |
| Net loss attributable to CareDx, Inc. | $(1,813) | $(19,970) | $18,157 |

#### Testing Services Revenue

Testing services revenue increased by $11.4 million, or 68%, for the three months ended September 30, 2019 as compared to the same period in 2018. This increase is primarily due to the 8,524 AlloSure Kidney patient results provided in the three months ended September 30, 2019, compared to 3,708 in the same period in 2018. Additionally, AlloMap Heart patient results increased to 4,726 in the three months ended September 30, 2019, compared to 4,080 in the same period in 2018.

#### Product Revenue

Product revenue remained constant at $4.2 million for the three months ended September 30, 2019, compared to the same period in 2018. This is a result of an increase in sales of TruSight HLA and QTYPE products, offset by decreased sales of Olerup SSP and Olerup SBT products.

#### Digital and Other Revenue

Digital and other revenue increased by $1.3 million for the three months ended September 30, 2019 compared to the same period in 2018, primarily due to the acquisition of Ottr in May 2019 and XynManagement in August 2019.

#### Cost of Revenue and Gross Profit

Cost of revenue increased by approximately $2.6 million, or 29%, for the three months ended September 30, 2019, compared to the same period in 2018, primarily due an increase in testing volume and the acquisitions of Ottr in May 2019 and XynManagement in August 2019.

Gross profit increased by $10.0 million, or 81%, for the three months ended September 30, 2019, compared to the same period in 2018, primarily due to an increase in revenue and an improvement in gross profit margins resulting from efficiencies in testing services laboratory operations.

#### Research and Development

Research and development expenses increased by $4.7 million, or 120%, for the three months ended September 30, 2019, compared to the same period in 2018, primarily due to a $3.9 million increase in personnel-related costs, a $0.6 million increase in consulting and professional fees and a $0.5 million increase in clinical studies, partially offset by lower consumable expenditures of $0.8 million.

#### Sales and Marketing

Sales and marketing expenses increased by approximately $5.1 million, or 85%, for the three months ended September 30, 2019, compared to the same period in 2018, primarily due to a $2.4 million increase in personnel-related costs, a $0.9 million increase in stock-based compensation expense, a $0.8 million increase in tradeshows, sponsorships and other marketing materials and a $0.5 million increase in travel costs.

#### General and Administrative

General and administrative expenses increased by $4.3 million, or 83%, for the three months ended September 30, 2019, compared to the same period in 2018. This increase was primarily due to a $2.7 million increase in stock-based compensation, a $0.7 million increase in consulting services for Sarbanes-Oxley Act compliance and other matters, a $0.6 million increase in personnel-related costs and a $0.2 million increase in legal fees.

#### Change in Estimated Fair Value of Common Stock Warrant Liability and Derivative Liability

The change in estimated fair value of common stock warrants and derivative liability changed from an expense of $17.1 million for the three months ended September 30, 2018 to income of $4.3 million for the three months ended September 30, 2019, resulting in a net change of $21.4 million, or 125%.

The $4.3 million income in the three months ended September 30, 2019 consisted of a fair market value adjustment for outstanding warrants. This remeasurement gain reflects the decrease in the price of shares of our common stock, and the reduction of the remaining expected term of outstanding warrants during the three months ended September 30, 2019.

The $17.1 million expense in the three months ended September 30, 2018 consisted of a $10.2 million charge related to warrants exercised during the period and a $6.9 million fair market value adjustment for outstanding warrants. These remeasurement charges reflect the increase in the price of shares of our common stock during the three months ended September 30, 2018.

### Comparison of Nine Months Ended September 30, 2019 and 2018

### (In thousands)

| Revenue: | Nine Months Ended September 30, 2019 | 2018 | Change |
| --- | ---: | ---: | ---: |
| Testing services revenue | $75,421 | $41,448 | $33,973 |
| Product revenue | 13,226 | 11,080 | 2,146 |
| Digital and other revenue | 2,600 | 532 | 2,068 |
| Total revenue | 91,247 | 53,060 | 38,187 |
| Cost of revenue | 32,739 | 22,478 | 10,261 |
| Gross profit | 58,508 | 30,582 | 27,926 |
| Operating expenses: |  |  |  |
| Research and development | 21,765 | 10,732 | 11,033 |
| Sales and marketing | 28,627 | 15,916 | 12,711 |
| General and administrative | 27,103 | 16,080 | 11,023 |
| Change in estimated fair value of contingent consideration | — | 1,017 | (1,017) |
| Total operating expenses | 77,495 | 43,745 | 33,750 |
| Loss from operations | (18,987) | (13,163) | (5,824) |
| Other income (expense): |  |  |  |
| Interest income (expense), net | 679 | (3,527) | 4,206 |
| Debt extinguishment expenses | — | (2,806) | 2,806 |
| Change in estimated fair value of common stock warrant liability and derivative liability | (14) | (24,540) | 24,526 |
| Other expense, net | (644) | (85) | (559) |
| Total other income (expense) | 21 | (30,958) | 30,979 |
| Loss before income taxes | (18,966) | (44,121) | 25,155 |
| Income tax benefit | 1,775 | 1,095 | 680 |
| Net loss | (17,191) | (43,026) | 25,835 |
| Net loss attributable to noncontrolling interest | — | (25) | 25 |
| Net loss attributable to CareDx, Inc. | $(17,191) | $(43,001) | $25,810 |

#### Testing Services Revenue

Testing services revenue increased by $34.0 million, or 82%, for the nine months ended September 30, 2019, compared to the same period in 2018. This increase is mainly due to an increase in volume of AlloSure Kidney patient results, with 21,589 AlloSure Kidney patient results provided in the nine months ended September 30, 2019, compared to 7,059 in the same period in 2018. Additionally, AlloMap Heart patient results increased to 13,578 in the nine months ended September 30, 2019, compared to 12,059 in the same period in 2018.

#### Product Revenue

Product revenue increased by $2.1 million, or 19%, for the nine months ended September 30, 2019, compared to the same period in 2018, primarily due to nine months of sales of TruSight HLA products for the nine months ended September 30, 2019 compared to four months of sales of TruSight HLA products for the nine months ended September 30, 2018 following the License Agreement with Illumina which was signed in May 2018. QTYPE sales also increased, partially offset by decreased sales of Olerup SSP and Olerup SBT products.

#### Digital and Other Revenue

Digital and other revenue increased by $2.1 million for the nine months ended September 30, 2019, compared to the same period in 2018, due to the acquisitions of Ottr in May 2019 and XynManagement in August 2019, resulting in $2.5 million of digital revenue, partially offset by a $0.4 million reduction of other revenue.

#### Cost of Revenue and Gross Profit

Cost of revenue increased by $10.3 million, or 46%, for the nine months ended September 30, 2019 due to an increase in the cost of testing service revenue of $7.7 million as a result of higher testing volume, an increase in cost of product revenue of $0.9 million due to increased product sales, and an increase in cost of digital and other revenue of $1.6 million as a result of the acquisitions of Ottr in May 2019 and XynManagement in August 2019.

Gross profit increased by $27.9 million, or 91%, for the nine months ended September 30, 2019, compared to the same period in 2018, primarily due to an increase in revenue and an improvement in gross profit margins resulting from efficiencies in testing services laboratory operations.

#### Research and Development

Research and development expenses increased by $11.0 million, or 103%, for the nine months ended September 30, 2019, compared to the same period in 2018. This increase is due to a $9.0 million increase in personnel-related costs, a $1.6 million increase in stock-based compensation expense, a $1.1 million increase in consulting and professional costs and a $0.7 million increase in clinical studies, partially offset by lower consumable expenditures of $1.9 million.

#### Sales and Marketing

Sales and marketing expenses increased by $12.7 million, or 80%, for the nine months ended September 30, 2019, compared to the same period in 2018, primarily due to an increase in personnel-related costs of $5.7 million, tradeshow and marketing costs of $2.9 million and stock-based compensation costs of $2.1 million.

#### General and Administrative

General and administrative expenses increased by $11.0 million, or 69%, for the nine months ended September 30, 2019, compared to the same period in 2018. This increase is primarily due to a $6.8 million increase in stock-based compensation expense, a $2.5 million increase in personnel-related costs, a $1.5 million increase in legal fees and a $1.0 million increase in consulting services for Sarbanes-Oxley Act compliance and other matters.

#### Change in Estimated Fair Value of Contingent Consideration

We estimated the contingent consideration liability fair value at each period end based on our common stock price at the end of the period and a probability of meeting the contractual milestone related to the number of patient results by June 2020, in accordance with the ImmuMetrix, Inc. acquisition agreement. The contingent consideration liability was settled in the nine months ended September 30, 2018, with the achievement of the contractual milestone of 2,500 AlloSure Kidney patient results. The $1.0 million expense reflected an increase in our share price from January 1, 2018 to the date of the issuance of the 227,848 shares and the settlement of the liability.

#### Interest Income (Expense), net

For the nine months ended September 30, 2019, we recorded interest income of $0.9 million related to interest earned by our money market accounts, offset by a $0.2 million accretion expense.

For the nine months ended September 30, 2018, interest expense of $3.5 million consisted of $2.4 million of interest expense and debt discount amortization related to our convertible debt (the “JGB Debt”), $0.9 million of interest expense and debt amortization recorded in relation to the Perceptive Credit Agreement entered into on April 17, 2018 and $0.2 million of interest expense recorded on the Allenex Notes, the Danske Bank Term Loan and the SSP Primers Loan.

#### Debt Extinguishment Expenses

For the nine months ended September 30, 2019, there was no debt extinguishment expense. For the nine months ended September 30, 2018, debt extinguishment expense was $2.8 million related to a loss recorded on the conversion of the JGB Debt, calculated as the difference between the value of the shares of common stock issued on the days of conversion and the amount of principal debt converted on those days, net of the allocated debt discount and derivative liability balances.

#### Change in Estimated Fair Value of Common Stock Warrant Liability and Derivative Liability

The expense for the change in estimated fair value of common stock warrants decreased by $24.5 million, or 100%, for the nine months ended September 30, 2019, compared to the same period in 2018. The expense in the nine months ended September 30, 2019 was $14 thousand, comprised of a $1.0 million remeasurement charge for warrants exercised during the period and a $1.0 million remeasurement gain related to the change in fair value of our common stock warrant liability.

The $24.5 million expense in the nine months ended September 30, 2018 consisted of a $18.2 million remeasurement charge for warrants exercised during the period and a $8.9 million remeasurement charge related to the changes in fair value of our remaining common stock warrant liability. These remeasurement charges reflect the increase in the price of shares of our common stock during the nine months ended September 30, 2018. These expenses were partially offset by a $2.6 million gain recorded for the changes in fair value of the JGB Debt embedded derivative between January 1, 2018 and the conversion date of March 27, 2018.

#### Other Expense, net

Other expense, net increased by $0.6 million for the nine months ended September 30, 2019, compared to the same period in 2018. The increase is primarily related to a foreign currency loss in the nine months ended September 30, 2019.

### Cash Flows for the Nine Months Ended September 30, 2019 and 2018

The following table summarizes the primary sources and uses of cash for the periods presented:

*(in thousands)*

| Net cash (used in) provided by: | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: |
| Operating activities | $(1,686) | $(6,005) |
| Investing activities | (21,237) | (6,969) |
| Financing activities | (214) | 12,956 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (493) | (62) |
| Net decrease in cash, cash equivalents and restricted cash | $(23,630) | $(80) |

#### Operating Activities

Net cash used in operating activities consists of net loss, adjusted for certain noncash items in the condensed consolidated statement of operations and changes in operating assets and liabilities.

Cash used in operating activities for the nine months ended September 30, 2019 was $1.7 million. Our net loss of $17.2 million was our primary use of cash in operating activities and included a number of noncash items. Our noncash items included a $17.0 million stock-based compensation expense, and a $3.8 million of depreciation and amortization expense. Net operating assets decreased by $6.6 million.

Cash used in operating activities for the nine months ended September 30, 2018 was $6.0 million. Our net loss of $43.0 million was our primary use of cash in operating activities and included a number of noncash items. Our noncash items included a $24.5 million loss on the revaluation of common stock warrant and derivative liabilities to estimated fair value, a $5.1 million stock-based compensation expense, $3.0 million of depreciation and amortization expense, $2.8 million loss on the conversion of debt to shares of our common stock, $2.2 million amortization expense related to the JGB Debt discount, $1.0 million contingent consideration revaluation expense and $0.2 million of amortization expense of inventory on fair market value adjustment. Net operating assets decreased by $1.8 million.

#### Investing Activities

For the nine months ended September 30, 2019, net cash used in investing activities was $21.2 million and consisted of $18.1 million related to the acquisitions of Ottr and XynManagement, $1.1 million related to acquisition of intangible assets, $1.0 million related to investment in equity securities, and investments of $1.0 million related to additions of capital expenditures.

For the nine months ended September 30, 2018, net cash used in investing activities was $7.0 million and consisted of $5.2 million related to the acquisition of intangible assets per the Illumina License Agreement, $1.1 million for purchases of property and equipment and $0.7 million for the acquisition of the Allenex minority interest.

#### Financing Activities

For the nine months ended September 30, 2019, net cash used in financing activities of $0.2 million was primarily related to taxes paid related to net share settlement of restricted stock units of $4.0 million, partially offset by proceeds from exercise of stock options of $3.2 million and proceeds from the issuance of common stock pursuant to our employee stock purchase plan of $0.8 million.

For the nine months ended September 30, 2018, net cash provided by financing activities of $13.0 million was primarily related to the $14.3 million net proceeds from the Perceptive Credit Agreement, cash proceeds of $11.0 million from the exercise of warrants and $0.6 million cash proceeds from the exercise of stock options, partially offset by $11.4 million of principal payments of the promissory notes issued to FastPartner AB and Mohammed Al Amoudi, the Danske Term Loan and the SSP Primers Loan, $0.7 million related to the repurchase of common stock under employee incentive plans, a $0.7 million repayment of the Danske Credit Facility and $0.2 million related to the acquisition of Conexio Genomics Pty Ltd.

### Liquidity and Capital Resources

We have incurred significant losses and negative cash flows from operations since our inception and had an accumulated deficit of $329.0 million at September 30, 2019. As of September 30, 2019, we had cash and cash equivalents of $40.9 million and no debt outstanding.

### Factors Affecting Our Performance

#### The Number of AlloMap Heart and AlloSure Kidney Tests We Receive and Report

The growth of our testing services business is tied to the number of AlloMap Heart and AlloSure Kidney patient samples we receive and patient results we report. We incur costs in connection with collecting and shipping all samples and a portion of the costs when we cannot ultimately issue a report. As a result, the number of patient samples received largely correlates directly to the number of patient results reported.

#### The Number of Diagnostic Products We Sell

The growth of our product revenues is tied to the sales of the Olerup SSP, QTYPE, Olerup SBT and TruSight HLA product lines. The product sales organizations are located in Stockholm, Sweden; Vienna, Austria; Fremantle, Australia and West Chester, Pennsylvania. Products are sold directly to customers in 14 countries. We also use distributors to sell products in approximately 60 countries.

#### Continued Adoption of and Reimbursement for AlloMap Heart

AlloMap Heart test volume and the corresponding reimbursement revenue has generally increased over time since the launch of AlloMap Heart, as Medicare provided reimbursement and payers adopt coverage policies and fewer payers consider AlloMap Heart to be experimental and investigational. The rate at which our tests are covered and reimbursed has, and is expected to continue to vary by payer. Revenue growth depends on our ability to maintain Medicare reimbursement, achieve broader reimbursement from third party payers and to expand the number of tests per patient and the base of healthcare providers.

The Protecting Access to Medicare Act of 2014, or PAMA, includes a substantial new payment system for clinical laboratory tests under the Clinical Laboratory Fee Schedule, or CLFS. Under PAMA, laboratories that receive the majority of their Medicare revenues from payments made under the CLFS would report initially and then on a subsequent three-year basis thereafter (or annually for advanced diagnostic laboratory tests, or ADLTs), private payer payment rates and volumes for their tests. The final PAMA ruling was issued June 17, 2016 indicating that data for reporting for the new PAMA process would begin in 2017 and the new market based rates took effect on January 1, 2018. Effective January 1, 2018, Medicare reimburses us $3,240 for AlloMap Heart testing of Medicare beneficiaries, an increase from the 2017 reimbursement rate of $2,841. AlloMap Heart has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers, including Aetna, Anthem, Cigna, Health Care Services Corporation (HCSC), Humana, Kaiser Foundation Health Plan, Inc., TRICARE and UnitedHealthcare.

#### Reimbursement for AlloSure Kidney

On September 26, 2017 we received notice that the MolDX Program developed by Palmetto GBA had set AlloSure Kidney reimbursement at $2,841. Effective October 9, 2017, AlloSure Kidney was made available for commercial testing with Medicare coverage and reimbursement. We believe the use of AlloSure Kidney, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a kidney transplant. In particular, we believe AlloSure Kidney can improve patient care by helping healthcare providers to reduce the use of invasive biopsies and determine the appropriate dosage levels of immunosuppressants.

#### Continued Growth of Product Sales

We develop, manufacture, market and sell products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP is used to type HLA alleles based on SSP technology. Olerup SBT is a complete product range for sequence-based typing of HLA alleles. QTYPE enables speed and precision in HLA typing at a low to intermediate resolution for samples that require a fast turn-around time and uses real-time PCR methodology. QTYPE received CE mark certification on April 10, 2018.

In May 2018, we entered into the License Agreement with Illumina, which provides us with worldwide distribution, development and commercialization rights to Illumina’s NGS product line for use in transplantation diagnostic testing. As a result, from June 1, 2018, we are the exclusive worldwide distributor of Illumina’s TruSight HLA v1 and v2 product line. In addition, we were also granted the exclusive right to develop and commercialize other NGS product lines for use in the Field, as defined in the agreement.

#### Continued Growth of Software Sales

The growth of our digital revenues is tied to the successful implementation of our Ottr and XynQAPI software businesses, as well as continued support and maintenance of existing Ottr and XynManagement customers. The Ottr software and XynQAPI are currently implemented in multiple locations in the U.S. The Ottr software implementation and support teams are based in Omaha, Nebraska. XynQAPI implementation and support teams are based in Boerne, Texas.

#### Development of Additional Products

We rely on sales of AlloMap Heart, AlloSure Kidney, Olerup SSP, Olerup SBT, QTYPE, TruSight HLA and our proprietary Ottr software to generate the majority of our revenue. Our development pipeline includes other transplant diagnostic solutions to help clinicians and transplant centers make personalized treatment decisions throughout a transplant patient’s lifetime, including HeartCare and KidneyCare. We expect to invest in research and development in order to develop additional products. Our success in developing new products and services will be important in our efforts to grow our business by expanding the potential market for our products and diversifying our sources of revenue.

#### Timing of Research and Development Expenses

Our spending on research and development may vary substantially from quarter to quarter. We also expend funds to secure clinical samples that can be used in discovery, product development, clinical validation, utility and outcome studies. The timing of these research and development activities is difficult to predict. If a substantial number of clinical samples are acquired in a given quarter or if a high-cost experiment is conducted in one quarter versus the next, the timing of these expenses will affect our financial results. We conduct clinical studies to validate our new products, as well as on-going clinical and outcome studies to further the published evidence to support our commercialized tests. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.

### Contractual Obligations

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.

### Off-Balance Sheet Arrangements

As of September 30, 2019, we had no off-balance sheet arrangements as defined under Regulation S-K 303(a)(4) of the Exchange Act, and the instructions thereto.

### JOBS Act Accounting Election

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

### Foreign Operations

The accompanying unaudited condensed consolidated balance sheets contain certain recorded assets in foreign countries, namely Stockholm, Sweden, Vienna, Austria and Fremantle, Australia. Although these countries are considered economically stable and we have experienced no notable burden from foreign exchange transactions, export duties or government regulations, unanticipated events in foreign countries could have a material adverse effect on our operations.

## Market risk

As filed, 1,794 characters.

#### Interest Rate Risk

We are exposed to market risks in the ordinary course of our business. We had cash and cash equivalents of $40.9 million and $64.6 million at September 30, 2019 and December 31, 2018, respectively, which consisted of bank deposits and money market funds. However, we have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates.

#### Foreign Currency Exchange Risk

We have operations in Sweden, Austria, Australia and sell to other countries throughout the world. As a result, we are subject to significant foreign currency risks, including transacting in foreign currencies, investment in a foreign entity, as well as assets and debts denominated in foreign currencies. Our testing services revenue is primarily denominated in U.S. dollars. Our product revenue is denominated primarily in Euro and U.S. dollars. Consequently, our revenue denominated in foreign currency is subject to foreign currency exchange risk. A portion of our operating expenses are incurred outside of the U.S. and are denominated in Swedish Krona, the Euro, and the Australian Dollar, which are also subject to fluctuations due to changes in foreign currency exchange rates. An unfavorable 10% change in foreign currency exchange rates for our assets and liabilities denominated in foreign currencies at September 30, 2019, would have negatively impacted our financial results for the nine months ended September 30, 2019 by $0.1 million and our product revenue by $0.6 million. Currently, we do not have any near-term plans to enter into a formal hedging program to mitigate the effects of foreign currency volatility. We will continue to reassess our approach to managing our risk relating to fluctuations in foreign currency exchange rates.

## Controls and procedures

As filed, 1,960 characters.

### Evaluation of Disclosure Controls and Procedures

Management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(b) and 15d-15(e) promulgated under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that we are required to apply our judgment in evaluating the benefits of possible controls and procedures relative to our costs. Based on such evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective at the reasonable assurance level and are effective to provide reasonable assurance that information required to be disclosed in the reports we file and submit under the Exchange Act, is (i) recorded, processed, summarized and reported as and when required and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the nine months ended September 30, 2019 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 3,678 characters.

Our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 6, 2019, Part I –Item 1A, Risk Factors, describes important risk factors that could cause our business, financial condition, results of operations and growth prospects to differ materially from those indicated or suggested by forward-looking statements made in this Quarterly Report on Form 10-Q or presented elsewhere by management from time to time. There have been no material changes in the risk factors that appear in Part I - Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 6, 2019, other than those listed below. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business.

***We may not be able to successfully integrate our business with the business of Ottr Complete Transplant Management, or Ottr, or XynManagement, Inc., or XynManagement, and we may not be able to achieve the anticipated strategic benefits from our acquisition of Ottr.***

The integration of Ottr, XynManagement and any other businesses or assets we may acquire will be a time-consuming process. The integration process will require substantial management time and attention, which may divert attention and resources from other important areas, including our existing business. In addition, we may not be able to fully realize the anticipated strategic benefits of any such combination, which includes, with respect to Ottr, the complementary Ottr software, and, with respect to XynManagement, XynQAPI, and in each case significant cross-selling opportunities. The failure to successfully integrate the combined operations, including retention of key employees, could impact our ability to realize the full benefits of our acquisition of Ottr, XynManagement or any other businesses or assets we may acquire. If we are not able to achieve the anticipated strategic benefits of any such combination, it could adversely affect our business, financial condition and results of operations, and could adversely affect the market price of our common stock if the integration or the anticipated financial and strategic benefits of the acquisition are not realized as rapidly as, or to the extent anticipated by investors and analysts. Failure to achieve these anticipated benefits could result in increased costs and decreases in future revenue and/or net income following the acquisition.

***Our License and Commercialization Agreement, or Cibiltech Agreement, with Cibiltech SAS, or Cibiltech, may not result in material benefits to our business.***

The Cibiltech Agreement provides us an exclusive right to commercialize its proprietary software Predigraft (or KidneyCare iBox in the U.S.). KidneyCare iBox will be initially provided to patients as part of the commencement of the Outcomes of KidneyCare on Renal Allografts study, or OKRA. OKRA is a prospective, multi-center, observational, registry of patients receiving KidneyCare for surveillance. KidneyCare combines the dd-cfDNA analysis of AlloSure Kidney with the gene expression profiling technology of AlloMap Kidney and the predictive artificial intelligence technology of KidneyCare iBox in one surveillance solution. We have not yet made any applications to payers for reimbursement coverage of AlloMap Kidney or KidneyCare iBox. The failure to obtain reimbursement coverage from payers for KidneyCare iBox could result in material amounts of revenue not being recognized, and failure to successfully integrate predictive artificial intelligence technology with our existing tests.

Filed Oct 31, 2019.
Source: SEC EDGAR, the filing index for accession 0001628280-19-012991. Last ingested by Listed: Nov 13, 2026, 16:18 ET. No prices; not investment advice.
